A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Degarelix (Primary) ; Gonadotropin releasing hormone stimulants
- Indications Prostate cancer
- Focus Pharmacodynamics
- 11 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results (n=80) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 13 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.